A Phase 3, Randomized, Double-blind, Add-on Study Evaluating the Safety and Efficacy of Navtemadlin Plus Ruxolitinib vs Placebo Plus Ruxolitinib in JAK Inhibitor-Nave Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

Disease Sites:

Hematologic

Staging:

Phase III

Age Group:

Adults

Therapies:

Mol. targeted/Immunotherapy/Biologics

Drugs:

Navtemadilin, Placebo, Ruxolitinib

Principal Investigator(s):

Mohan, Sanjay

Scope:

National

Participating Institutions:

Vanderbilt University

Open Date:

08-25-2025

Trial Type:

Treatment

Protocol ID:

VICC-DTHEM24136

National Clinical Trial ID:

NCT06479135

Eligibility

Ages Eligible for Study:

Not Available

Genders Eligible for Study:

Not Available

Accepts Healthy Volunteers?:

Not Available